A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The bile salt export pump (BSEP) is expressed at the canalicular domain of hepatocytes, where it serves as the primary route of elimination for monovalent bile acids (BAs) into the bile canaliculi. The most compelling evidence linking dysfunction in BA transport with liver injury in humans is found with carriers of mutations that render BSEP nonfunctional. Based on mounting evidence, there appears to be a strong association between drug-induced BSEP interference and liver injury in humans; however, causality has not been established. For this reason, drug-induced BSEP interference is best considered a susceptibility factor for liver injury as other host- or drug-related properties may contribute to the development of hepatotoxicity. To better understand the association between BSEP interference and liver injury in humans, over 600 marketed or withdrawn drugs were evaluated in BSEP expressing membrane vesicles. The example of a compound that failed during phase 1 human trials is also described, AMG 009. AMG 009 showed evidence of liver injury in humans that was not predicted by preclinical safety studies, and BSEP inhibition was implicated. For 109 of the drugs with some effect on in vitro BSEP function, clinical use, associations with hepatotoxicity, pharmacokinetic data, and other information were annotated. A steady state concentration (C(ss)) for each of these annotated drugs was estimated, and a ratio between this value and measured IC₅₀ potency values were calculated in an attempt to relate exposure to in vitro potencies. When factoring for exposure, 95% of the annotated compounds with a C(ss)/BSEP IC₅₀ ratio ≥ 0.1 were associated with some form of liver injury. We then investigated the relationship between clinical evidence of liver injury and effects to multidrug resistance-associated proteins (MRPs) believed to play a role in BA homeostasis. The effect of 600+ drugs on MRP2, MRP3, and MRP4 function was also evaluated in membrane vesicle assays. Drugs with a C(ss)/BSEP IC₅₀ ratio ≥ 0.1 and a C(ss)/MRP IC₅₀ ratio ≥ 0.1 had almost a 100% correlation with some evidence of liver injury in humans. These data suggest that integration of exposure data, and knowledge of an effect to not only BSEP but also one or more of the MRPs, is a useful tool for informing the potential for liver injury due to altered BA transport.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering that mechanisms leading to alterations in bile-acid homeostasis are believed in part to be responsible for recent prominent late-stage clinical attritions and black box warnings of novel therapeutics, including examples such as CP-724,714 (Feng et al. 2009), tolvaptan (Slizgi et al. 2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al. 2017)”
From Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury (2017) · cites this paper as Morgan et al. 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The 1996 Guide for the Care and Use of Laboratory Animals
Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E., & Kohn, D. F. (1997) · ILAR Journal · doi:10.1093/ilar.38.1.41 · Cited by 4,417
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 4×
“…the concordance between preclinical animal safety data and human clinical outcomes for 150 development compounds and found that hepatotoxicity ( 60% concordance) and cutaneous/hypersensitivity reactions ( 40% concordance) were the 2 poorest predicted adverse events (Olson et al., 2000).”
BackgroundInfluentialBile salt transporters: molecular characterization, function, and regulation
Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00027.2002 · Cited by 999 · cited 3×
“To mitigate potential cytotoxicity, BA homeostasis is tightly regulated by metabolic, excretion, absorption, and feedback mechanisms to limit their intracellular accumulation (Trauner and Boyer, 2003).”
BackgroundStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., & Meier, P. J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70224-1 · Cited by 582
Fattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
The apical conjugate efflux pump ABCC2 (MRP2)
Nies, A. T., & Keppler, D. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0109-y · Cited by 398
Dawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Zollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
Cited by
Mechanistic diversity in ATP-binding cassette (ABC) transporters.
Locher, K. P. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3216 · Cited by 804
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
“2016), AMG-009 (Morgan et al. 2013), and TAK-875 (Wolenski et al.”
BackgroundInfluentialBindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data
Liu, T., Hwang, L., Burley, S. K., Nitsche, C. I., Southan, C., Walters, W. P., & Gilson, M. K. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1075 · Cited by 236
“…(SAR) for a given protein target ( 28 ); reports of new data for many compounds against a panel of kinases ( 29 ); large ADME-related studies ( 30 ,31 ); publications associated with datasets within the PDSP database ( 32 ,33 ); and review articles or articles with large datasets assembled…”
Zamek‐Gliszczynski, M. J., Taub, M. E., Chothe, P. P., Chu, X., Giacomini, K. M., Kim, R. B., Ray, A. S., Stocker, S. L., Unadkat, J. D., Wittwer, M. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1112 · Cited by 231
Renal Drug Transporters and Drug Interactions
Ivanyuk, A., Livio, F., Biollaz, J., & Buclin, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0506-8 · Cited by 221
Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management
Mosedale, M., & Watkins, P. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.564 · Cited by 203
“DILI-causing drugs can disrupt this process in many ways, most importantly through reducing hepatic bile acid efflux by inhibition of the bile salt export protein (BSEP).(14) This results in the intracellular accumulation of toxic bile acids, which can lead to hepatocyte death.”
BackgroundToxicology Strategies for Drug Discovery: Present and Future
Blomme, E. A. G., & Will, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00407 · Cited by 194
Köck, K., Ferslew, B. C., Netterberg, I., Yang, K., Urban, T. J., Swaan, P. W., Stewart, P. W., & Brouwer, K. L. R. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054304 · Cited by 159
“Recently, several large studies systematically investigated the relationship between DILI and BSEP inhibition using BSEP membrane vesicles (Morgan et al., 2010; Dawson et al., 2012; Morgan et al., 2013).”
BackgroundHepatic 3D spheroid models for the detection and study of compounds with cholestatic liability
Hendriks, D. F. G., Fredriksson Puigvert, L., Messner, S., Mortiz, W., & Ingelman-Sundberg, M. (2016) · Scientific Reports · doi:10.1038/srep35434 · Cited by 156
In vitro platforms for evaluating liver toxicity
Bale, S. S., Vernetti, L., Senutovitch, N., Jindal, R., Hegde, M., Gough, A., McCarty, W. J., Bakan, A., Bhushan, A., Shun, T. Y., et al. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214531872 · Cited by 155
Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., & Aleo, M. D. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv152 · Cited by 148
“For example, most-DILI compounds such as nefazodone, troglitazone, benzbromarone with triple liabilities in our analysis are also known to form covalent adducts, are positive for cytotoxicity in a THLE cell line selectively expressing CYP3A4, and are inhibitors of multidrug resistance-associated protein 4 (Morgan et a…”
BackgroundKenna, J. G., Taskar, K. S., Battista, C., Bourdet, D. L., Brouwer, K. L. R., Brouwer, K. R., Dai, D., Funk, C., Hafey, M. J., Lai, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1222 · Cited by 123
“In addition, numerous drugs that caused DILI and inhibited BSEP also inhibited MRP2 activity in hepatocyte(40) and membrane vesicle(18,19) assays, although overall a poor concordance between inhibition of the two transporters by drugs was observed.(18,19) In humans, multidrug resistance protein 3 (MDR3, encoded by ABC…”
BackgroundMethodInfluentialBeyer, D., Hoff, J., Sommerfeld, O., Zipprich, A., Gaßler, N., & Press, A. T. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00510-8 · Cited by 140
“Above all, many drugs (for BSEP circa 600 substances) act as competitive inhibitors and impair the functionality of these transporters, thus triggering disturbances in the metabolism of endogenous or exogenous substances (Morgan et al. 2013).”
BackgroundSpecies differences in bile acids I. Plasma and urine bile acid composition
Thakare, R., Alamoudi, J. A., Gautam, N., Rodrigues, A. D., & Alnouti, Y. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3644 · Cited by 112
“For example, bosentan, troglitazone, AMG009 and ximelagatran were not hepatotoxic in rats but they cause DILI in humans (Lepist et al., 2014; Mohankumar et al., 2015; Morgan et al., 2013; Schadt et al., 2016).”
BackgroundMechanisms of drug-induced liver injury
Stephens, C., Andrade, R. J., & Lucena, M. I. (2014) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000070 · Cited by 110
“This has led to a heightened alert for BSEP activity as a hepatotoxicity potential in drug development [24].”
BackgroundPatlewicz, G., Simon, T. W., Rowlands, J. C., Budinsky, R. A., & Becker, R. A. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.02.011 · Cited by 108
“In fact, as will be seen, the incorporation of exposure is often critical for increasing the predictive power of models (Morgan et al., 2013).”
BackgroundRodrigues, A. D., Lai, Y., Cvijic, M. E., Elkin, L. L., Zvyaga, T. A., & Soars, M. G. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054205 · Cited by 113
“Interestingly, during the preparation of the present manuscript, Morgan et al. (2013) reported that integration of exposure data and knowledge of drug effect to not only BSEP but also one or more of the MRPs is a useful tool for informing the potential for DILI resulting from altered bile acid…”
BackgroundCase Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury
Ortega-Alonso, A., Stephens, C., Lucena, M., & Andrade, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050714 · Cited by 104
“Therefore, in the screening of drug compounds with toxic potential, it is more accurate to consider BSEP inhibition along with the activity of other liver transporters [83,84].”
BackgroundYang, K., Woodhead, J. L., Watkins, P. B., Howell, B. A., & Brouwer, K. L. R. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.158 · Cited by 95
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
Woodhead, J. L., Yang, K., Siler, S. Q., Watkins, P. B., Brouwer, K. L. R., Barton, H. A., & Howell, B. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00240 · Cited by 93
Sharanek, A., Burban, A., Burbank, M., Le Guevel, R., Li, R., Guillouzo, A., & Guguen-Guillouzo, C. (2016) · Scientific Reports · doi:10.1038/srep24709 · Cited by 93
“(3) DCA, ANIT, bosentan and ML-9 inhibited Ca2+/CaM-dependent MLCK instead of ROCK and led to BC dilation.”
BackgroundWoodhead, J. L., Brock, W. J., Roth, S. E., Shoaf, S. E., Brouwer, K. L. R., Church, R. J., Grammatopoulos, T. N., Stiles, L., Siler, S. Q., Howell, B. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw193 · Cited by 96
“The association between compounds that inhibit hepatic transporters and liver safety liabilities is strengthened further by considering compound inhibition of multidrug resistance-associated proteins (MRPs) (Morgan et al., 2013).”
Minimizing DILI risk in drug discovery — A screening tool for drug candidates
Schadt, S., Simon, S., Kustermann, S., Boess, F., McGinnis, C., Brink, A., Lieven, R., Fowler, S., Youdim, K., Ullah, M., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.09.019 · Cited by 89
Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury
Yang, K., Guo, C., Woodhead, J. L., St. Claire, R. L., Watkins, P. B., Siler, S. Q., Howell, B. A., & Brouwer, K. L. R. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.008 · Cited by 85
Otieno, M. A., Snoeys, J., Lam, W. W., Ghosh, A., Player, M. R., Pocai, A., Salter, R., Simic, D., Skaggs, H. S., Singh, B., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx040 · Cited by 89
“Transporter inhibition experiments were conducted as previously described (Morgan et al., 2013).”
MethodLepist, E., Gillies, H., Smith, W. R., Jia, H., Hubert, C., Claire, R. L. S., Brouwer, K. R., & Ray, A. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087548 · Cited by 77
“1 had an almost 100% correlation with some evidence of liver injury in humans [30].”
BackgroundLongo, D., Yang, Y., Watkins, P., Howell, B., & Siler, S. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12053 · Cited by 73
“In addition, recent work using in vitro systems has demonstrated that both drugs have the potential to alter hepatobiliary transport.(10) Tolcapone and entacapone caused modest inhibition of the bile salt export pump (BSEP), an efflux transporter that secretes bile acids (BAs) from the liver into the bile, and the bas…”
BackgroundInfluentialCellular Accumulation and Toxic Effects of Bile Acids in Cyclosporine A-Treated HepaRG Hepatocytes
Sharanek, A., Burban, A., Humbert, L., Azzi, P. B.-E., Felix-Gomes, N., Rainteau, D. P., & Guillouzo, A. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv155 · Cited by 70
“Many drugs are recognized to cause idiosyncratic cholestasis (Grattagliano et al., 2009; Morgan et al., 2013) Because of their various physiological roles and their in-”
BackgroundMeasures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI
Chan, R., & Benet, L. Z. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx284 · Cited by 69
“Thus, we believe the results of Tables 7 and 8 do not support the Morgan et al. (2013) recommendation.”
BackgroundMethodResultInfluentialWoodhead, J. L., Yang, K., Oldach, D., MacLauchlin, C., FERNANDES, P. B., Watkins, P. B., Siler, S. Q., & Howell, B. A. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2582-y · Cited by 73
“The combination of in vitro assay results with measures of exposure has been shown to produce an increased ability to predict liver toxicity beyond that of the assay alone (30); the combination of in vitro assay results, exposure estimates, and known biological variability contained by QST models such as DILIsym can p…”
BackgroundCheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
Current limitations and future opportunities for prediction of DILI from in vitro
Funk, C., & Roth, A. B. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1874-9 · Cited by 67
Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside
Beaudoin, J. J., Brouwer, K. L. R., & Malinen, M. M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107542 · Cited by 69
Gilibili, R. R., Chatterjee, S., Bagul, P., Mosure, K. W., Murali, B. V., Mariappan, T. T., Mandlekar, S., & Lai, Y. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074740 · Cited by 61
“3) (Morgan et al., 2013), these compounds appeared to be inhibitors in MRP2-mediated CP-I transport (Table 1).”
BackgroundResultInfluentialComedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™
Suzuki, A., Yuen, N. A., Ilic, K., Miller, R. T., Reese, M. J., Brown, H. R., Ambroso, J. I., Falls, J. G., & Hunt, C. M. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.05.004 · Cited by 58
Zamek‐Gliszczynski, M. J., Sangha, V., Shen, H., Feng, B., Wittwer, M., Varma, M. V. S., Liang, X., Sugiyama, Y., Zhang, L., & Bendayan, R. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2644 · Cited by 61
“However, if compounds and/or their glucuronide conjugates are potent MRP2 inhibitors, MRP3 and MRP4 inhibition may be prudent to additionally be considered if liver injury is observed.(106,107)”
BackgroundHunt, C. M., Yuen, N., Stirnadel-Farrant, H. A., & Suzuki, A. (2014) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2014.09.007 · Cited by 64
Dragovic, S., Vermeulen, N. P. E., Gerets, H. H., Hewitt, P. G., Ingelman‐Sundberg, M., Park, B. K., Juhila, S., Snoeys, J., & Weaver, R. J. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1845-1 · Cited by 58
“In addition, recent work has demonstrated that both drugs have the potential to alter hepatobiliary transport causing modest inhibition of the BSEP and the basolateral efflux transporters (MRP3 and MRP4) (Morgan et al. 2013).”
BackgroundBurbank, M., Burban, A., Sharanek, A., Weaver, R. J., Guguen‐Guillouzo, C., & Guillouzo, A. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071373 · Cited by 69
Aleo, M. D., Shah, F., Allen, S. W., Barton, H. A., Costales, C., Lazzaro, S., Leung, L. Y., Nilson, A. L., Obach, R. S., Rodrigues, A. D., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00262 · Cited by 58
Species differences in bile acids II. Bile acid metabolism
Thakare, R. N., Alamoudi, J. A., Gautam, N., Rodrigues, A. D., & Alnouti, Y. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3645 · Cited by 61
“For example, telmisartan is a potent BSEP inhibitor, but is not associated with DILI in the clinic (Morgan et al., 2013).”
BackgroundSlizgi, J. R., Lu, Y., Brouwer, K. R., St. Claire, R. L., Freeman, K. M., Pan, M., Brock, W. J., & Brouwer, K. L. R. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfv231 · Cited by 53
“The ratio between the concentration at steady state (Css) or maximal plasma concentration (Cmax) and the inhibitory potency (IC50) is used commonly to understand the relationship between drug or metabolite exposure and inhibition (Morgan et al., 2013; Zhang, 2012).”
BackgroundResultInfluentialYang, K., Pfeifer, N. D., Köck, K., & Brouwer, K. L. R. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221564 · Cited by 57
“TGZ has been reported to inhibit the basolateral efflux transporters MRP3 and MRP4 (Morgan et al., 2013),”
BackgroundResultInfluentialMechanisms of drug induced liver injury
Skat‐Rørdam, J., Lykkesfeldt, J., Gluud, L. L., & Tveden‐Nyborg, P. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05744-3 · Cited by 69
“…ability to induce mitochondrial stress, inhibit hepatocellular transporters or calculating polygenic risk scores for HLA alleles, while methods for determining ER stress, bile acid canaliculi dynamics and cytoskeletal alterations as well as immune responses are less established [10 , 31, 123 ].”
InfluentialBecker, R. A., Friedman, K. P., Simon, T. W., Marty, M. S., Patlewicz, G. Y., & Rowlands, J. C. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.01.008 · Cited by 51
Recent advances in the exploration of the bile salt export pump (BSEP/ABCB11) function
Telbisz, Á., & Homolya, L. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1102889 · Cited by 55
“These methods are established and validated in high throughput BSEP in vitro drug interaction datasets, which were significantly expanded recently [10, 67, 68, 84, 87-91].”
BackgroundMethodIn Vitro Models for Studying Chronic Drug-Induced Liver Injury
Donato, M. T., Ferrer, G. G., & Tolosa, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911428 · Cited by 54
“, erythromycin, bosentan, cyclosporine, itraconazole and ethynyl estradiol) [74].”
BackgroundMalinen, M. M., Ali, I., Tiley, J. B., Beaudoin, J. J., & Brouwer, K. L. R. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00310.2017 · Cited by 55
Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury
Mosedale, M., & Watkins, P. B. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01297 · Cited by 53
Kenna, J. G., Stahl, S. H., Eakins, J. A., Foster, A. J., Andersson, L. C., Bergare, J., Billger, M., Elebring, M., Elmore, C. S., & Thompson, R. A. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220491 · Cited by 48
Qiu, X., Zhang, Y., Liu, T., Shen, H., Xiao, Y., Bourner, M. J., Pratt, J. R., Thompson, D. C., Marathe, P., Humphreys, W. G., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00659 · Cited by 52
Wolenski, F. S., Zhu, A. Z. X., Johnson, M., Yu, S., Moriya, Y., Ebihara, T., Csizmadia, V., Grieves, J. L., Paton, M., Liao, M., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx018 · Cited by 49
“The hypothesis tested in the nonclinical studies was that TAK-875 alters bile acid (BA) homeostasis, which may be a contributing factor to drug induced liver injury (DILI).”
BackgroundInfluentialRoth, S. E., Avigan, M. I., Bourdet, D., Brott, D., Church, R., Dash, A., Keller, D., Sherratt, P., Watkins, P. B., Westcott‐Baker, L., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1571 · Cited by 42
Zhang, J., He, K., Cai, L., Chen, Y.-C., Yang, Y., Shi, Q., Woolf, T. F., Ge, W., Guo, L., Borlak, J., et al. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.03.019 · Cited by 44
“However, this membrane vesicle assay lacks the capacity to assess the role of in situ drug metabolism, and therefore could generate false negative results if a metabolite causes inhibition or false positive results if a drug is rapidly metabolized to inactive metabolites, when compared with clinical outcomes [3,8,9].”
BackgroundMethodResultInfluentialSelf-citationQosa, H., Avaritt, B. R., Hartman, N. R., & Volpe, D. A. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3665-x · Cited by 46
Analytical and Omics-Based Advances in the Study of Drug-Induced Liver Injury
Kralj, T., Brouwer, K. L. R., & Creek, D. J. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab069 · Cited by 44
“5 mM; troglitazone, IC50 1⁄4 3 mM) (Jackson et al., 2018; Morgan et al., 2013).”
BackgroundDrug–Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization
Gan, J., Zhang, H., & Humphreys, W. G. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00274 · Cited by 46
Susukida, T., Sekine, S., Nozaki, M., Tokizono, M., & Ito, K. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065425 · Cited by 45
“We do not have a clear basis for setting the test drug concentration to 50 mM, but this value is empirically chosen based on previous studies (Morgan et al., 2010, 2013; Pedersen et al., 2013; Aleo et al., 2014; Kock et al., 2014).”
BackgroundMethodResultInfluentialWeaver, R. J., Betts, C., Blomme, E. A. G., Gerets, H. H. J., Gjervig Jensen, K., Hewitt, P. G., Juhila, S., Labbe, G., Liguori, M. J., Mesens, N., et al. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1341489 · Cited by 42
“ter proteins in screens with varying degrees of success [67,68].”
BackgroundGill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115885 · Cited by 41
Novel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors
Saran, C., Sundqvist, L., Ho, H. S. S., Niskanen, J., Honkakoski, P., & Brouwer, K. L. R. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000828 · Cited by 44
“The sorafenib-mediated increase in the bile acid metabolite GCDCA-3G in SCHH and medium may be due to increased bile acid glucuronidation via uridine 5 0 -diphospho-glucurono- syltransferase (UGTs) and/or altered transport via MRPs. Inhibition of MRP2 and MRP4 by sorafenib is consistent with previous in vitro studies…”
BackgroundResultInfluentialAleo, M. D., Shah, F., He, K., Bonin, P. D., & Rodrigues, A. D. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00048 · Cited by 41
Inhibition of MDR3 Activity in Human Hepatocytes by Drugs Associated with Liver Injury
He, K., Cai, L., Shi, Q., Liu, H., & Woolf, T. F. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00201 · Cited by 41
Welch, M. A., Köck, K., Urban, T. J., Brouwer, K. L. R., & Swaan, P. W. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062539 · Cited by 44
“726 Welch et al. The pharmacophore models for BSEP inhibition were generated from a subset of drugs from the BSEP training set that were the strongest inhibitors ( , 25 uM IC 50 s) among the Morgan dataset (Morgan et al., 2013).”
BackgroundMethodInfluentialBarber, J. A., Stahl, S. H., Summers, C., Barrett, G., Park, B. K., Foster, J. R., & Kenna, J. G. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv159 · Cited by 39
Sistare, F. D., Mattes, W. B., & LeCluyse, E. L. (2016) · ILAR Journal · doi:10.1093/ilar/ilw025 · Cited by 40
Lei, J., Zhai, J., Zhang, Y., Qi, J., & Sun, C. (2025) · Journal of Medical Internet Research · doi:10.2196/66733 · Cited by 46
“In sepsis, inflammation not only reduces the anchoring of these transporters to the membrane [26], but also a significant number of drugs—acting as competitive inhibitors—can impair their function, leading to severe metabolic disturbances [27,28].”
Gough, A., Vernetti, L. A., Bergenthal, L., Shun, T. Y., & Taylor, D. L. (2016) · Applied In Vitro Toxicology · doi:10.1089/aivt.2016.0011 · Cited by 37
“Bile efflux was 97% inhibited by 88 lM tolcapone, a finding consistent with earlier reports.(55) The higher concentration of tolcapone produced excessive toxicity by day 5; the time bile efflux is reestablished in the in vitro liver and therefore was not tested.”
Cheng, Y., Woolf, T. F., Gan, J., & He, K. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.11.029 · Cited by 36
Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis
Vitale, G., Mattiaccio, A., Conti, A., Berardi, S., Vero, V., Turco, L., Seri, M., & Morelli, M. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065823 · Cited by 36
“Inhibition of BSEP-mediated transport is one of the mechanisms that cause DIC [48,49].”
Backgroundvan Ertvelde, J., Verhoeven, A., Maerten, A., Cooreman, A., Rodrigues, B. D. S., Sanz-Serrano, J., Mihajlovic, M., Tripodi, I. J., Teunis, M., Jover, R., et al. (2023) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2023.104465 · Cited by 41
Dambach, D. M., Misner, D., Brock, M., Fullerton, A. M., Proctor, W. R., Maher, J. M., Lee, D. H., Ford, K. A., & Diaz, D. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00396 · Cited by 37
Yucha, R. W., He, K., Shi, Q., Cai, L., Nakashita, Y., Xia, C. Q., & Liao, M. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx060 · Cited by 35
“IC50 Cutoff Criteria Takeda (50 cpds) Amgen (50 cpds) IC50 Cutoff (mM) PPV NPV Sensitivity Specificity PPV NPV Sensitivity Specificity”
BackgroundMethodResultInfluentialFlagging Drugs That Inhibit the Bile Salt Export Pump
Montanari, F., Pinto, M., Khunweeraphong, N., Wlcek, K., Sohail, M. I., Noeske, T., Boyer, S. K., Chiba, P., Stieger, B., Kuchler, K., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00594 · Cited by 37
Shoda, L. K. M., Battista, C., Siler, S. Q., Pisetsky, D. S., Watkins, P. B., & Howell, B. A. (2017) · Gene Regulation and Systems Biology · doi:10.1177/1177625017696074 · Cited by 34
“dt I MR M PR M AR lsec j lsec j lsec lsec j lsec j lsec j lsec j , , , , , , = − − (7)”
BackgroundRole of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)—In Vitro Testing
Tátrai, P., Erdő, F., & Krajcsi, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010029 · Cited by 35
Principles of precision medicine and its application in toxicology
Cook, J. C., Wu, H., Aleo, M. D., & Adkins, K. (2018) · The Journal of Toxicological Sciences · doi:10.2131/jts.43.565 · Cited by 33
“Additionally, AMG009 and TAK875 have been shown to cause DILI via inhibiting multiple bile salt efflux transporters (Morgan et al., 2013; Otieno et al., 2017).”
Ritschel, T., Hermans, S. M. A., Schreurs, M., van den Heuvel, J. J. M. W., Koenderink, J. B., Greupink, R., & Rüssel, F. G. M. (2014) · Chemical Research in Toxicology · doi:10.1021/tx5000393 · Cited by 34
Stem cell models as an in vitro model for predictive toxicology
Lynch, S., Pridgeon, C. S., Duckworth, C. A., Sharma, P., Park, B. K., & Goldring, C. E. (2019) · Biochemical Journal · doi:10.1042/bcj20170780 · Cited by 36
Namasivayam, V., Silbermann, K., Pahnke, J., Wiese, M., & Stefan, S. M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.05.018 · Cited by 36
Establishment of a Drug-Induced, Bile Acid–Dependent Hepatotoxicity Model Using HepaRG Cells
Susukida, T., Sekine, S., Nozaki, M., Tokizono, M., Oizumi, K., Horie, T., & Ito, K. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.01.013 · Cited by 32
Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?
Kenna, J. G., & Uetrecht, J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.082719 · Cited by 32
“(Dawson et al., 2012; Morgan et al., 2013; Yucha et al., 2017).”
BackgroundInfluentialIn silico toxicity evaluation of Salubrinal and its analogues
Zadorozhnii, P. V., Kiselev, V. V., & Kharchenko, A. V. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105538 · Cited by 33
Fernández-Murga, M. L., Petrov, P., Conde, I., Castell, J. V., Gómez‐Lechón, M. J., & Jover, R. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.07.017 · Cited by 32
Ferslew, B. C., Köck, K., Bridges, A. S., & Brouwer, K. L. R. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057554 · Cited by 28
“…together with frequent coadministration of potent MRP4 inhibitors [i.e., glyburide, fluoxetine, furosemide, simvastatin (Köck et al., 2013; Morgan et al., 2013)] may unpredictably alter hepatic and systemic concentrations of drugs/ metabolites that are transported in a manner similar to…”
BackgroundLepist, E., & Ray, A. S. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1372425 · Cited by 28
“BSEP inhibition has been the focus of attempts to proactively predict drug-induced liver injury (DILI) due to the association of BSEP inhibition with reported liver toxicity for a large number of clinically tested drugs [21,103,104].”
BackgroundLu, X., Liu, L., Shan, W., Kong, L., Chen, N., Lou, Y., & Zeng, S. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190426152830 · Cited by 31
Brecklinghaus, T., Albrecht, W., Kappenberg, F., Duda, J., Vartak, N., Edlund, K., Marchan, R., Ghallab, A., Cadenas, C., Günther, G., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109728 · Cited by 32
“This assay has been reported to detect BSEP inhibition at relatively low concentrations [33].”
BackgroundMethodInfluentialCheng, Y., El‐Kattan, A. F., Zhang, Y., Ray, A. S., & Lai, Y. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00511 · Cited by 27
Role of Hepatic Drug Transporters in Drug Development
Liu, H., & Sahi, J. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.703 · Cited by 32
Ali, I., Welch, M. A., Lu, Y. Y., Swaan, P. W., & Brouwer, K. L. R. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.02.011 · Cited by 28
“Factoring in the inhibition of other compensatory bile acid efflux transporters, including multidrug resistance-associated protein (MRP) 2, MRP3, and MRP4, can improve DILI predictions (Köck et al., 2014; Morgan et al., 2013).”
Jackson, J. P., Freeman, K., Claire, R. L. S., Black, C., & Brouwer, K. R. (2018) · Applied In Vitro Toxicology · doi:10.1089/aivt.2018.0011 · Cited by 29
“8,9 Therefore, early cholestatic DILI screening efforts have focused on a compound’s potential to inhibit BSEP transport using recombinant vesicles.”
Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity
Saran, C., & Brouwer, K. L. R. (2023) · Toxicologic Pathology · doi:10.1177/01926233231212255 · Cited by 30
“5,62 However, the mechanism(s) of hepato-toxicity associated with TKIs beyond BSEP inhibition were poorly understood.”
BackgroundKohara, H., Bajaj, P., Yamanaka, K., Miyawaki, A., Harada, K., Miyamoto, K., Matsui, T., Okai, Y., Wagoner, M. P., & Shinozawa, T. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz229 · Cited by 26
Beaudoin, J. J., Bezençon, J., Sjöstedt, N., Fallon, J. K., & Brouwer, K. L. R. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa052 · Cited by 26
“Dysregulation of bile acid disposition, particularly by drugmediated inhibition of hepatic efflux transporters, can lead to hepatocellular accumulation of toxic bile acid species resulting in liver damage (Dawson et al., 2012; Köck et al., 2014; Morgan et al., 2013; Perez and Briz, 2009).”
BackgroundCepa, S. P., Potter, D., Wong, L., Schutt, L., Tarrant, J. M., Pang, J., Zhang, X., Andaya, R., Salphati, L., Ran, Y., et al. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.11.007 · Cited by 27
Self-citationCurrent insights in the complexities underlying drug-induced cholestasis
Deferm, N., Vocht, T. D., Qi, B., Brantegem, P. V., Gijbels, E., Vinken, M., de Witte, P. A. M., Bouillon, T. W., & Annaert, P. (2019) · Critical Reviews in Toxicology · doi:10.1080/10408444.2019.1635081 · Cited by 27
“These systems are valuable tools to investigate the involvement of BSEP inhibition in DIC, but fail in accurately predicting human DIC, as they reduce the mechanistic complexity of DIC to merely the interaction of one transporter.”
BackgroundInfluentialMachine Learning Models to Predict Inhibition of the Bile Salt Export Pump
McLoughlin, K., Jeong, C. G., Sweitzer, T. D., Minnich, A., Tse, M. J., Bennion, B. J., Allen, J., Calad-Thomson, S., Rush, T. S., & Brase, J. M. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00950 · Cited by 23
Antibiotic-induced Elevations of Plasma Bile Acids in Rats Independent of Bsep Inhibition
Li, Y., Hafey, M. J., Duong, H., Evers, R., Cheon, K., Holder, D., Galijatovic-Idrizbegovic, A., Sistare, F. D., & Glaab, W. E. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx015 · Cited by 26
Troglitazone Inhibits Bile Acid Amidation: A Possible Risk Factor for Liver Injury
Ogimura, E., Nakagawa, T., Deguchi, J., Sekine, S., Ito, K., & Bando, K. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx091 · Cited by 28
Metadata
- Authors
- Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K.
- Affiliations
- Amgen (United States) (US)
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-16
- Volume
- 136
- Issue
- 1
- Pages
- 216-241
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2152548885
- Cited by
- 243
- References
- 41
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 14 · 2023: 14 · 2022: 15 · 2021: 13 · 2020: 12 · 2019: 24 · 2018: 20 · 2017: 33 · 2016: 30 · 2015: 24 · 2014: 11 · 2013: 2
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- bile salt export pump, drug-induced liver injury, hepatotoxicity, bile acid transport, multidrug resistance-associated protein, MRP2, MRP3, MRP4, steady-state concentration, hepatobiliary transporters, drug safety assessment
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily B, Member 11, Animals, Biological Transport, Humans, Liver, Male, Pharmacokinetics, Recombinant Proteins, Risk Factors, Cluster Analysis, Rats, Sprague-Dawley, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, Risk Assessment, Toxicity Tests, ATP-Binding Cassette, Sub-Family C Proteins, Rats, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.